Plain-English translation of NCT06513962 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether triptorelin, a medication that temporarily pauses the ovaries, can protect egg supply in adolescents and young adults undergoing chemotherapy for cancer. Some chemotherapy drugs can damage the ovaries and reduce fertility, which is a serious concern for young women facing cancer treatment. The study will compare young women who receive triptorelin alongside their regular chemotherapy to those who receive chemotherapy alone.
Many cancer treatments are lifesaving but can harm the ovaries and reduce a woman's ability to have biological children later in life. Researchers believe this medication might protect the eggs by temporarily quieting the ovaries during the most damaging phase of chemotherapy, potentially preserving future fertility options.
You likely qualify if…
You likely don't qualify if…
You would receive either triptorelin injections (given before or shortly after starting chemotherapy) plus your standard cancer treatment, or just your standard cancer treatment alone. Throughout the study, you'll have regular blood tests to measure hormone levels and egg supply. After your chemotherapy is finished, you'll return for follow-up visits and blood tests at 1 year and 2 years to see how your ovarian health is doing.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States